Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2004-000337-12-HU (EUCTR)	23/07/2004	29/09/2004	A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects with Relapsing Remitting Multiple Sclerosis - EMEA Post Approval Commitment New Clone Study	A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects with Relapsing Remitting Multiple Sclerosis - EMEA Post Approval Commitment New Clone Study	MS with 2 or more relapses within the last 2 years MedDRA version: 7.0;Level: PT;Classification code 10028245	Trade Name: Rebif Product Name: Rebif Product Code: Not applicable INN or Proposed INN: Interferon beta -1a Other descriptive name: Recombinant human interferon beta Trade Name: Rebif Product Name: Rebif Product Code: Not applicable INN or Proposed INN: Interferon beta -1a Other descriptive name: Recombinant human interferon beta	Serono International SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	400	Phase 4	Hungary